New partnership to market Optim systems.
We are pleased to announce that we entered into an agreement with Pall Corporation, a global leader in filtration, separation and purification, to sell and distribute Avacta’s market leading protein drug development tool “Optim” in South East Asia. This agreement extends Avacta’s commercial partnership with Pall, with whom the Group is already making good progress on sales and marketing of Optim in North America.
Under the terms of the extended collaboration, Pall will gain exclusive marketing and distribution rights to Optim, in a number of territories throughout the Pacific Rim including South Korea, Australia, New Zealand and Singapore. Singapore, home to Pall’s ‘Centre of Excellence’, will also act as a central hub for Malaysia, Indonesia, Thailand and Vietnam.
Optim is an innovative technology that provides biopharmaceutical developers with information about the viability of their candidate drug molecules and formulations for R&D purposes and to optimise manufacturing. Optim can provide this data very early in the drug development process thereby avoiding later stage costly product failures.
The biopharma market for South East Asia is set for growth, with Singapore as a particular hotspot. Several leading global pharmaceutical companies have recently announced significant investments to set up major biologics facilities in the region. The prospects for the South Korean bio-industry also look very promising due to strong government support and investments by international and regional businesses.
Alastair Smith, Chief Executive of Avacta Group commented: “We are delighted to expand our collaboration with Pall further and to benefit from their expertise and resources in the South East Asian market. We are very pleased with the progress that Pall are making with Optim sales and marketing in North America and expect to see the same sort of progress in this new territory. The strengthening of our commercial partnership with Pall through the development of a joint analytical services offering, that was recently announced, and potential to develop new products together is very important to Avacta and we anticipate that this will provide a strong platform for growth in this area of the Group’s activities.”
Ken Frank Senior Vice President of Pall Corporation and President of Pall’s Biopharmaceutical Division commented: “The extension of our collaboration with Avacta in South East Asia complements our investments in this area and significantly furthers our capability to provide high value, differentiated solutions to the developers and manufacturers of biomolecules for global healthcare needs.”